Huahai Pharmaceutical's Subsidiary Huatai Enters Global Research Partnership and Licensing Deal with ALM

Stock News03-27

Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with Almirall, S.A. The partnership focuses on developing monoclonal antibody candidate drugs targeting novel mechanisms for multiple potential indications, including medical dermatology. Under the agreement, Huatai retains rights to develop and commercialize the program and resulting products in China, while ALM holds exclusive global development and commercialization rights outside of China. Huatai will conduct research using its innovative R&D platform through the proof-of-concept clinical stage. ALM will make an upfront payment to Huatai, along with development and commercial milestone payments totaling up to $340 million, plus tiered royalties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130865147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130865147","market":"us","top_or_hot":-1,"title":"Huahai Pharmaceutical's Subsidiary Huatai Enters Global Research Partnership and Licensing Deal with ALM","media":"Stock News","content":"<p>Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with Almirall, S.A. The partnership focuses on developing monoclonal antibody candidate drugs targeting novel mechanisms for multiple potential indications, including medical dermatology. Under the agreement, Huatai retains rights to develop and commercialize the program and resulting products in China, while ALM holds exclusive global development and commercialization rights outside of China. Huatai will conduct research using its innovative R&D platform through the proof-of-concept clinical stage. ALM will make an upfront payment to Huatai, along with development and commercial milestone payments totaling up to $340 million, plus tiered royalties.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huahai Pharmaceutical's Subsidiary Huatai Enters Global Research Partnership and Licensing Deal with ALM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuahai Pharmaceutical's Subsidiary Huatai Enters Global Research Partnership and Licensing Deal with ALM\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 16:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with Almirall, S.A. The partnership focuses on developing monoclonal antibody candidate drugs targeting novel mechanisms for multiple potential indications, including medical dermatology. Under the agreement, Huatai retains rights to develop and commercialize the program and resulting products in China, while ALM holds exclusive global development and commercialization rights outside of China. Huatai will conduct research using its innovative R&D platform through the proof-of-concept clinical stage. ALM will make an upfront payment to Huatai, along with development and commercial milestone payments totaling up to $340 million, plus tiered royalties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALM","symbol_name":"Almonty Industries Inc. (NASDAQ Uplisting)","start_time":0,"source_url":"","article_id":"1130865147","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130865147","pubTimestamp":1774599857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600521":"华海药业","ALM":"Almonty Industries Inc. (NASDAQ Uplisting)","BK0188":"融资融券","BK0239":"医药制造","BK0028":"国家队","BK0185":"二线龙头","BK4168":"多种金属与采矿","BK0201":"可转债","BK0070":"员工持股","BK0012":"证金概念"},"translate_title":"华海药业子公司华泰与ALM达成全球研究合作伙伴关系和许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1,"ALM":1},"content_text":"Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with Almirall, S.A. The partnership focuses on developing monoclonal antibody candidate drugs targeting novel mechanisms for multiple potential indications, including medical dermatology. Under the agreement, Huatai retains rights to develop and commercialize the program and resulting products in China, while ALM holds exclusive global development and commercialization rights outside of China. Huatai will conduct research using its innovative R&D platform through the proof-of-concept clinical stage. ALM will make an upfront payment to Huatai, along with development and commercial milestone payments totaling up to $340 million, plus tiered royalties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130865147","isCrawlerRequest":true}